SWM
BPMC

Spire Wealth Management’s Blueprint Medicines BPMC Stock Holding History

Spire Wealth Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-110
Closed -$9.59K – 2480
2024
Q4 		$9.59K Buy
+110
New +$10.1K ﹤0.01% 1843
2022
Q4 		– Sell
-80
Closed -$5K – 2314
2022
Q3 		$5K Hold
80
– – ﹤0.01% 1728
2022
Q2 		$4K Hold
80
– – ﹤0.01% 2172
2022
Q1 		$5K Hold
80
– – ﹤0.01% 2221
2021
Q4 		$9K Hold
80
– – ﹤0.01% 2406
2021
Q3 		$8K Hold
80
– – ﹤0.01% 2147
2021
Q2 		$7K Hold
80
– – ﹤0.01% 2218
2021
Q1 		$8K Buy
+80
New +$7.99K ﹤0.01% 2468

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Spire Wealth Management's BPMC Position: Q1 2025 in Review

Spire Wealth Management sold out of Blueprint Medicines (BPMC) in Q1 2025, closing a stake of 110 shares — an estimated $9.59K sold.

Spire Wealth Management first reported a position in BPMC in Q1 2021 and held it in 8 quarters. The position peaked at $9.59K in Q4 2024. 352 funds tracked by Wall St. Rank hold BPMC as of Q1 2025.

  • Spire Wealth Management reported no remaining Blueprint Medicines position as of Q1 2025 after selling out during the quarter.
  • Spire Wealth Management sold 110 Blueprint Medicines shares in Q1 2025, an estimated $9.59K.
  • Spire Wealth Management first reported a position in Blueprint Medicines in Q1 2021 and held it in 8 quarters.
  • Spire Wealth Management's Blueprint Medicines position peaked at $9.59K in Q4 2024.
  • 352 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2025.

Based on Spire Wealth Management's 13F filing for Q1 2025, filed 23 Apr 2025.